Activities for the Development of Targeted Radionuclide Therapy in Japan
10.1007/s13139-018-0563-4
- Author:
Seigo KINUYA
1
Author Information
1. Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. kinuya@med.kanazawa-u.ac.jp
- Publication Type:Brief Communication
- Keywords:
Targeted radionuclide therapy;
Theranostics;
Japan;
Governmental support
- MeSH:
Asian Continental Ancestry Group;
Humans;
Japan;
Nuclear Medicine;
Precision Medicine;
Social Control, Formal;
Theranostic Nanomedicine
- From:Nuclear Medicine and Molecular Imaging
2019;53(1):35-37
- CountryRepublic of Korea
- Language:English
-
Abstract:
Targeted radionuclide therapy (TRT) is unique because of its efficacy and its theranostic feature in the era of precision medicine. So far, introduction of new TRT has not been going well in Japan due to several reasons including strict regulations, shortage of facilities for TRT, and insufficient reimbursement for TRT in clinic. Japanese community had several strategies to develop TRT in these 10 years, including the establishment of the National Conference for Nuclear Medicine Theranostics in which physicians, scientists, patients, people supporting patients, and industrial people gather. To promote TRTwith supports from the government, the preparatory committee for the establishment of Japan Foundation of Medical Isotope Development (JAFMID) was launched. I would like to call TRT “Precision Nuclear Medicine.” When we can add genomic information here, we can put it to new stage of cancer therapy. It is time for us.
